Medicare's $50 Weight-Loss Drug Program Launches This Week: What Older Adults Need to Know
Medicare's new $50/month weight-loss drug program launches July 1, offering GLP-1 medications to 3.8 million eligible seniors, but doctors urge caution on.
30 articles
Medicare's new $50/month weight-loss drug program launches July 1, offering GLP-1 medications to 3.8 million eligible seniors, but doctors urge caution on.
GLP-1 drugs like semaglutide cause up to 45% muscle loss with weight, but protein targets and resistance training can largely prevent it.
Intermittent fasting matches calorie counting for weight loss but offers a key bonus: people think about food far less, new research finds.
Setting a weight loss goal before starting Zepbound led to significantly better results, a study of 81,000 people found.
Retatrutide, a new weight-loss drug, helped trial participants lose 30% of their body weight, surpassing Ozempic and matching bariatric surgery results.
People taking Ozempic and Wegovy are walking 560 fewer steps daily after starting treatment, and experts say exercise must be part of any weight loss drug.
GLP-1 drugs like Zepbound now treat sleep apnea by targeting weight loss, with patients reducing breathing interruptions by up to 50%.
The American Medical Association adopts new policies to eliminate insurance barriers blocking patient access to weight-loss drugs like Ozempic.
New oral medication helps menopausal women lose up to 30 pounds in 72 weeks, with consistent weight loss results across all menopause stages.
New dual-action weight loss drug survodutide helped people lose 12% body weight while clearing dangerous liver fat in 84% of users.
Around 84% of weight lost on Wegovy and Mounjaro is fat, not muscle, new research shows, with functional strength remaining intact throughout.
About 15% of GLP-1 users are microdosing to cut costs and reduce side effects, but doctors warn there's no safety data on this approach.
Researchers created an experimental fat-burning pill that preserves muscle mass unlike Ozempic, targeting metabolism directly in early trials.
New research reveals 26% of people with normal BMI actually meet clinical obesity criteria, suggesting millions miss needed health screenings.
Scientists discover fat cells have a dual role beyond energy storage, potentially revolutionizing obesity treatment by focusing on cell health.
Semaglutide shows promise treating MASH, a silent liver disease affecting 250 million people, by reducing inflammation and reversing scarring.
Lower tirzepatide doses maintain weight loss long-term, with 5mg keeping off 16.6% body weight vs 9.9% for those who stopped treatment entirely.
Oral Wegovy delivers 21.6% weight loss in early responders and improves mobility in 77% of users with poor physical function, new trial data shows.
GLP-1 weight loss medications reduce calorie intake by up to 39%, creating dangerous nutritional gaps.
New research shows GLP-1 medications don't compromise bariatric surgery effectiveness.
GLP-1 weight loss drugs like Ozempic and Wegovy are linked to 42% fewer psychiatric hospital visits and 44% lower depression risk, while one in eight Americans...
The FDA has proposed excluding semaglutide and tirzepatide from compounding pharmacy lists, citing no clinical need.
New guidelines suggest looser blood sugar control may benefit most patients. Here's why experts are shifting away from aggressive targets and what it means for...
Rapid weight loss triggers temporary hair shedding in many people through a condition called telogen effluvium.
GLP-1 drugs like Ozempic and Wegovy are transforming weight management, but experts warn they may mask deeper societal issues around obesity while long-term...
A new study reveals that 11.7% of people are using weight loss medications without doctor oversight, often relying on social media for guidance.
A 5-year study of over 3,000 adults found that eating breakfast early and extending overnight fasts were linked to lower BMI, suggesting meal timing aligns...
Foundayo, Eli Lilly's new daily weight loss pill, loses to Zepbound injections in clinical trials.
Excess body weight causes 1 in 10 new cancers in the U.S., ranking second only to smoking.
A major study of nearly 28,000 people reveals genetic variants that predict weight loss success and side effects from GLP-1 medications like Ozempic and...